All In Biotech

Drug Trial Radar · NCT05626855

Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab

An Open-Label, Multicenter, Extension Trial to Evaluate the Long-Term Safety and Efficacy of Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy Who Completed Previous Investigational Trials of Apitegromab

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

238

Actual

Start

Apr 17, 2023

Primary completion

Nov 1, 2026

Study completion May 2, 2029

Sponsor

Lead sponsor
Scholar Rock, Inc.Industry
Sponsor type
Industry
First posted
Nov 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The ONYX study is an Open-Label, Multicenter, Extension study that will evaluate the long-term safety and efficacy of Apitegromab in Patients with Type 2 and Type 3 SMA who have completed TOPAZ or SAPPHIRE.

Conditions

  • Spinal Muscular Atrophy
  • Spinal Muscular Atrophy Type 3
  • Spinal Muscular Atrophy Type 2
  • SMA
  • Neuromuscular Diseases
  • Muscular Atrophy
  • Atrophy
  • Muscular Atrophy, Spinal
  • Neuromuscular Manifestations
  • Anti-myostatin

Interventions

  • ApitegromabDrug

    Apitegromab (SRK-015) is an investigational, fully human immunoglobulin G4 monoclonal antibody that specifically binds to human proforms (i.e., inactive precursor forms) of myostatin, pro- and latent- myostatin, with high affinity, inhibiting activation of myostatin, a negative regulator of muscle growth and strength.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the long-term safety and tolerability of apitegromab in patients with Type 2 and Type 3 SMATime frame: Up to 6 years

Locations

49 sites in 9 countries. Site status is shown where the registry gives one.

  • Phoenix Childrens Hospital

    Phoenix, Arizona

  • UCSD Altman Clinical and Translational Research

    La Jolla, California

  • Children's Hospital Los Angeles

    Los Angeles, California

  • Stanford Neuroscience Health Center

    Palo Alto, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Nemours Biomedical Research

    Orlando, Florida

  • Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • University of Kansas Medical Center

    Fairway, Kansas

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Boston Children's Hospital

    Boston, Massachusetts

  • Helen DeVos Children's Hospital

    Grand Rapids, Michigan

  • Gillette Children's Specialty Healthcare

    Saint Paul, Minnesota

  • Washington University Medical Campus

    St Louis, Missouri

  • Columbia University Medical Center

    New York, New York

  • Wake Forest University School of Medicine

    Winston-Salem, North Carolina

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

  • University of Texas Southwestern - Pediatric Neurology

    Dallas, Texas

  • University of Utah

    Salt Lake City, Utah

  • Children's Specialty Group PLLC (Children's Hospital of The King's Daughters)

    Newport News, Virginia

  • Seattle Children's Hospital

    Seattle, Washington

  • University of Wisconsin Hospital

    Madison, Wisconsin

  • UZ Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • CHR Citadelle

    Liège, Belgium

  • CHRU de Lille - Hpital Jeanne de Flandre

    Lille, France

  • Hopital Trousseau - I-Motion

    Paris, France

  • CHU Toulouse Hopital des Enfants

    Toulouse, France

  • Universitätskinderklinik Bonn, Abteilung für Neuropädiatrie und SPZ

    Bonn, Germany

  • Universitatsklinikum Essen

    Essen, Germany

  • Universitatsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Klinikum der Universitat Munchen, Dr. von Haunersches Kinderspital, Abteilung fur Kinderneurologie und Entwicklungsneurologie

    Munchen, Bayern, Germany

  • Istituto Giannina Gaslini, Centro Traslazionale di Miologia e Patologie Neurodegenerative

    Genova, Italy

  • UOC NEUROLOGIA E MALATTIE NEUROMUSCOLARI A.O.U Policlinico G. Martino

    Messina, Italy

  • Carlo Besta Neurological Research Institute

    Milan, Italy

  • NeuroMuscular Omnicentre

    Milan, Italy

  • Fondazione Policlinico Universitario A. Gemelli

    Roma, Italy

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.